• Explore /
  • Poster
  • / <span>Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.</span>

Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.

Abstract Poster

Authors

null

Ryan Phillips

Mayo Clinic, Rochester, MN

Ryan Phillips , James A. Proudfoot , Elai Davicioni , Yang Liu , Daniel Eidelberg Spratt , Felix Y Feng , Jeff Simko , Robert Benjamin Den , Alan Pollack , Seth A. Rosenthal , A. Oliver Sartor , Christopher Sweeney , Gerhardt Attard , Samir Patel , Michael Wayne Straza , Jason A. Efstathiou , Amit Shah , Joseph P. Rodgers , Howard M. Sandler , Phuoc T. Tran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5094)

DOI

10.1200/JCO.2023.41.16_suppl.5094

Abstract #

5094

Poster Bd #

188

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

First Author: Howard M. Sandler

First Author: Yuki Yoshikawa

First Author: Stephen Andrew Mihalcik

First Author: John Nikitas